At EASD26 in Milan, Regeneron presented data suggesting its antibody maintained clinically meaningful muscle-related outcomes in obesity patients who stopped Novo Nordisk’s Wegovy, with results indicating regained muscle mass comparable to what was lost during GLP-1 therapy. The mid-stage update adds to the growing obesity-and-body-composition focus of next-generation programs, where preserving lean mass and functional outcomes is becoming as central as weight loss. Investors and clinicians are likely to watch how these signals translate into broader patient populations and long-term durability, particularly as obesity regimens move toward combination strategies and discontinuation scenarios.